High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
High Mutation Counts May Predict Better Cancer Survival Outcomes
This systematic review and meta-analysis evaluated 5278 patients with solid tumours treated with immune checkpoint inhibitors or chemotherap…
High mutation counts in tumors may help predict who will survive longer when taking powerful immune-boosting cancer drugs
Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression
Five-year follow-up shows pembrolizumab extends life for Chinese lung cancer patients with high PD-L1
This Phase 3 trial evaluated pembrolizumab monotherapy against chemotherapy in Chinese patients with previously untreated locally advanced o…
A five-year look at a Chinese lung cancer trial shows pembrolizumab improved survival compared to chemotherapy for patients with high PD-L1 …
Subcutaneous tislelizumab shows comparable trough concentrations to intravenous dosing in treatment-naive advanced non-small cell lung cancer patients
Phase I trial shows subcutaneous tislelizumab reaches high drug levels in lung cancer patients
This phase I trial evaluated subcutaneous versus intravenous tislelizumab in treatment-naive patients with advanced non-small cell lung canc…
Early data suggest subcutaneous tislelizumab injections may offer similar drug levels to intravenous forms for treating advanced lung cancer…
RNK08954 shows unconfirmed responses in KRASG12D-mutant NSCLC and PDAC in Phase Ia trial
New drug shows promise for KRASG12D lung and pancreatic cancers
This phase Ia trial evaluated RNK08954 in 36 patients with KRASG12D-mutant non-small cell lung cancer or pancreatic ductal adenocarcinoma.
An early trial of RNK08954 shrank tumors in 58% of lung cancer patients with a specific KRAS mutation.
CT-based immune radiomic signature shows association with prognosis in non-small cell lung cancer
CT scans may help predict lung cancer treatment response
This cohort study utilized a CT-based immune radiomic signature, known as CT-RadScore, across multiple patient cohorts including TCIA, TCGA,…
A new way to analyze CT scans could help doctors predict how lung cancer patients respond to immunotherapy and other drugs.
CIPHER model predicts immune checkpoint inhibitor pneumonitis risk in non-small cell lung cancer patients
Lung Scans Can Now Predict Dangerous Side Effect Before Treatment
This cohort study evaluated a CIPHER model versus classical radiomic models for predicting immune checkpoint inhibitor-induced pneumonitis i…
This tool could help doctors protect patients before a serious side effect strikes.
Narrative review discusses tumor draining lymph nodes as a target for NSCLC therapy
Lymph Nodes Hold Key to Beating Lung Cancer
This narrative review examines the tumor draining lymph nodes (TDLN) microenvironment remodeling in non-small cell lung cancer (NSCLC).
You wake up, sip your coffee, and take your morning walk.
Narrative review examines abscopal effect potential in non-small cell lung cancer multimodality therapies
When One Tumor Shrinks, Others Can Too—Here’s How
This narrative review evaluates the abscopal effect in non-small cell lung cancer patients treated with radiotherapy, lung ablation, or immu…
A new review explains how treating one lung tumor can help shrink tumors elsewhere in the body, offering a new way to think about cancer tre…
Review of 68Ga-Pentixafor PET/CT Utility in Lung Cancer Diagnosis and Management
Lung Scans Get Smarter With New Imaging Tool
This narrative review examines the utility of 68Ga-Pentixafor PET/CT in patients with lung cancer.
You wake up, cough again — just like the past few weeks.
Preoperative inflammatory markers linked to survival in resectable NSCLC
Simple Blood Work Could Predict Lung Cancer Surgery Outcomes
This retrospective cohort study of 460 patients with resectable non-small cell lung cancer found that elevated preoperative inflammatory mar…
A new look at blood tests shows inflammation levels may help doctors plan better care for lung cancer patients.
Narrative review discusses osimertinib use in EGFR-mutated NSCLC patients with TKI resistance
Osimertinib may help some lung cancer patients after resistance develops
This narrative review examines the use of osimertinib and other EGFR-TKIs in non-small cell lung cancer patients harboring EGFR mutations af…
A review suggests osimertinib could be an option for non-small cell lung cancer patients with EGFR mutations who develop resistance to earli…
Meta-analysis shows local consolidative therapy plus systemic therapy improves survival in driver-negative oligometastatic NSCLC
For a specific lung cancer group, adding local treatment to standard drugs significantly improved survival time
This systematic review and meta-analysis evaluated local consolidative therapy combined with systemic therapy versus systemic therapy alone …
Adding local treatment to standard drugs significantly improved survival time for a specific lung cancer group with spread to only a few pla…